Dr. Cornelis “Marcel” E.C.A. Hop is Senior Director at Genentech (South San Francisco) and supervising the Drug Metabolism & Pharmacokinetics Department. He leads a team of about 75 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. He is also a member of the Small Molecule Leadership Team and the Development Review Committee. Before that he was a Senior Director at Pfizer (Groton, CT) and a Senior Research Fellow at Merck (Rahway, NJ). He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, and bioanalysis. He has authored more than 160 publications in refereed journals and several book chapters and made more than 75 external oral presentations at conferences and universities. Recently, he co-authored one of the best-selling books in the ADME field: Drug Metabolism and Pharmacokinetics Quick Guide.
His main professional interests are focused on innovative approaches to improve the efficiency of the drug discovery and development process and to reduce compound attrition with an emphasis on the use of artificial intelligence, in silico tools, and more comprehensive ways to predicted human pharmacokinetics and dose, including modeling & simulation.
He is a board member of the International Consortium for Innovation and Quality in Pharmaceutical Development and was chair of the Drug Metabolism Leadership Group (2014-2016). He is a member of the Scientific Affairs Committee of ISSX and a member of the Organizing Committee for the 23rd North American ISSX meeting in Portland,Oregon and was a member of the Organizing Committee for the 21st North American ISSX meeting in Providence, Rhode Island and the International Scientific Advisory Board for the 11th International ISSX meeting in Busan, South Korea. He chaired the 9th Clinical & Pharmaceutical Solutions through Analysis Conference in Shanghai in 2018. He was also on the Corporate Advisory Board of the School of Pharmacy, University of Washington-Seattle (2010-2016). He has organized several sessions at national and international meetings, is a member of several professional societies and a regular manuscript reviewer.
|12:05 PM - 12:45 PM||
Opportunities and Challenges Using AI in unlocking the ADME Tox Obstacles in Drug Development
This session will address how machine and active learning are being applied to solve complex and difficult ADME Tox problems facing the pharma industry. There will be representation from both in-house and external models as well as pro and con viewpoints on applying AI to the challenges of the ADME/tox field. Industry innovators and researchers share their efforts in solving these challenges which could be worth hundreds of millions to industry, accelerate drug discovery and be invaluable to patients.